Press Releases

The following UK & Ireland Press Releases contain information that is intended for journalists only.
For media enquiries about our press releases please contact mediaenquiries.UK-IE@ipsen.com.

CRSC-GB-000115

March 2024


7 results

NICE recommends Cabometyx® (cabozantinib) in combination wit...

Cabozantinib in combination with nivolumab recommended by NICE as a first-line therapy for untreated advanced…

Ipsen appoints Ioana Parsons as General Manager, U.K. & ...

LONDON, U.K., 6 March 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment…

Ipsen Wrexham investment unveiled as Wrexham mayor joins 50t...

WREXHAM, UK, 13 June 2023 – Ipsen today announced a £75 million investment in its…

Ipsen’s response to NICE’s decision on Cabometyx® (cabozanti...

SLOUGH, UK, 5th April 2023 – Ipsen is disappointed that the National Institute for Health…

NICE recommends Cabometyx® (cabozantinib) for previously tre...

Cabozantanib has been recommended by NICE as an option for treating advanced hepatocellular carcinoma (HCC),…

Tánaiste joins Ipsen Ireland to launch upgraded manufacturin...

Dublin, Ireland, 25th/26th September 2022 Tánaiste joins Ipsen Ireland to launch upgraded manufacturing site in…

Ipsen announced overall Pharma Industry Company of the Year ...

Ireland, May 2022 Blanchardstown-based, biopharmaceutical Ipsen has been announced overall Pharma Industry Company of the…

© Ipsen Group 2024